tradingkey.logo
tradingkey.logo
Search

Impact Biomedical Inc

IBO
Add to Watchlist
0.472USD
+0.003+0.68%
Close 07/02, 13:00ETQuotes delayed by 15 min
50.89MMarket Cap
LossP/E TTM

More Details of Impact Biomedical Inc Company

Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.

Impact Biomedical Inc Info

Ticker SymbolIBO
Company nameImpact Biomedical Inc
IPO dateSep 16, 2024
CEOHeuszel (Frank D)
Number of employees2
Security typeOrdinary Share
Fiscal year-endSep 16
Address1400 Broadfield Blvd.
CityHOUSTON
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code77084
Phone15852321500
Websitehttps://www.impactbiomedinc.com/
Ticker SymbolIBO
IPO dateSep 16, 2024
CEOHeuszel (Frank D)

Company Executives of Impact Biomedical Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
300.00K
--
Dr. Elise Brownell
Dr. Elise Brownell
Independent Director
Independent Director
300.00K
--
Ms. Melissa Sims
Ms. Melissa Sims
Independent Director
Independent Director
300.00K
--
Mr. Christian Zimmerman
Mr. Christian Zimmerman
Independent Director
Independent Director
300.00K
--
Mr. Castel B. Hibbert
Mr. Castel B. Hibbert
Independent Director
Independent Director
300.00K
--
Mr. Jason Grady
Mr. Jason Grady
Director
Director
250.18K
-19.99%
Mr. Heng Fai (Ambrose) Chan
Mr. Heng Fai (Ambrose) Chan
Director
Director
--
--
Mr. Frank D. Heuszel, CPA
Mr. Frank D. Heuszel, CPA
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Todd D. Macko
Mr. Todd D. Macko
Chief Financial Officer
Chief Financial Officer
--
--
Mr. David K. Keene
Mr. David K. Keene
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
300.00K
--
Dr. Elise Brownell
Dr. Elise Brownell
Independent Director
Independent Director
300.00K
--
Ms. Melissa Sims
Ms. Melissa Sims
Independent Director
Independent Director
300.00K
--
Mr. Christian Zimmerman
Mr. Christian Zimmerman
Independent Director
Independent Director
300.00K
--
Mr. Castel B. Hibbert
Mr. Castel B. Hibbert
Independent Director
Independent Director
300.00K
--
Mr. Jason Grady
Mr. Jason Grady
Director
Director
250.18K
-19.99%

FAQs

Who are the top five shareholders of Impact Biomedical Inc?

The top five shareholders of Impact Biomedical Inc are: Mr. Mark Suseck

How many institutions hold shares of Impact Biomedical Inc (IBO)?

As of 2026Q1, 37 institutions hold shares of Impact Biomedical Inc, with a combined market value of approximately 2.77M, accounting for 2.56% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 2084658.00.